Jonathan D. Enders
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jonathan D. Enders has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Cheryl Louise Stucky
Medical College of Wisconsin
5 shared publications Jarrid Jack
Cell Biology and Physiology, University of Kansas Medical Center, Kansas City, KS 66160, United States
4 shared publicationsPaige Lynch
Departments of Anesthesiology, University of Kansas Medical Center, Kansas City, KS 66160, United States
4 shared publicationsSarah Thomas
Departments of Anesthesiology, University of Kansas Medical Center, Kansas City, KS 66160, United States
4 shared publicationsAnvitha Sriram
Department of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI, 53226
3 shared publicationsJanelle M. Ryals
Departments of Anesthesiology, University of Kansas Medical Center, Kansas City, KS 66160, United States
3 shared publications
Latest Publications
- Open Access
Dyslipidemia is a metabolic hallmark of acute pain in sickle cell disease
Individuals with sickle cell disease (SCD) experience intense acute episodic pain associated with vaso-occlusive events and persistent, often daily, chronic pain. Triggers for acute episodic pain include cold exposure, strenuous exercise, and hypoxia. The molecular mechanisms underlying acute pain in SCD are poorly defined. We asked whether acute pain was associated with an altered metabolomic profile in individuals with SCD. We performed untargeted metabolomics on plasma from 25 children with SCD obtained during two disease states: 1) during an acute pain episode, and 2) during baseline state of health (“baseline health”). Control plasma was analyzed from 25 race-matched healthy controls. We identified 318 dysregulated metabolites in SCD patients during baseline health relative to healthy controls. Baseline health SCD samples had elevated pyrimidine, polyamine, and methionine metabolites, whereas arginine and sphingomyelin metabolites were decreased. During acute pain, we identified 448 dysregulated metabolites relative to baseline health conditions in the same SCD patients. We found decreased amino acid metabolites and acyl-carnitines, consistent with hypoxia. Network analysis revealed eight metabolic modules that were significantly differentially correlated to healthy controls, baseline health, or SCD acute pain. Modules enriched for porphyrin metabolism were correlated with SCD during acute and baseline health conditions. Other modules identified prominent dyslipidemia during acute pain in SCD relative to baseline health and healthy controls. Furthermore, we identified a metabolic module characterized by multiple sphingomyelins that were reduced in SCD and correlated with acute pain. Our findings identify dyslipidemia and impaired oxidative metabolism as potential drivers of acute pain in SCD.
Open AccessDyslipidemia is a metabolic hallmark of acute pain in sickle cell disease
Individuals with sickle cell disease (SCD) experience intense acute episodic pain associated with vaso-occlusive events and persistent, often daily, chronic pain. Triggers for acute episodic pain include cold exposure, strenuous exercise, and hypoxia. The molecular mechanisms underlying acute pain in SCD are poorly defined. We asked whether acute pain was associated with an altered metabolomic profile in individuals with SCD. We performed untargeted metabolomics on plasma from 25 children with SCD obtained during two disease states: 1) during an acute pain episode, and 2) during baseline state of health (“baseline health”). Control plasma was analyzed from 25 race-matched healthy controls. We identified 318 dysregulated metabolites in SCD patients during baseline health relative to healthy controls. Baseline health SCD samples had elevated pyrimidine, polyamine, and methionine metabolites, whereas arginine and sphingomyelin metabolites were decreased. During acute pain, we identified 448 dysregulated metabolites relative to baseline health conditions in the same SCD patients. We found decreased amino acid metabolites and acyl-carnitines, consistent with hypoxia. Network analysis revealed eight metabolic modules that were significantly differentially correlated to healthy controls, baseline health, or SCD acute pain. Modules enriched for porphyrin metabolism were correlated with SCD during acute and baseline health conditions. Other modules identified prominent dyslipidemia during acute pain in SCD relative to baseline health and healthy controls. Furthermore, we identified a metabolic module characterized by multiple sphingomyelins that were reduced in SCD and correlated with acute pain. Our findings identify dyslipidemia and impaired oxidative metabolism as potential drivers of acute pain in SCD.
- 8 December 2025
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (5) , 1238-1239
Reply to Chen and Yeh
- 8 December 2025
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (5) , 1238-1239
Reply to Chen and Yeh
- 3 October 2025
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (2) , 443-454
Episodic pain in Fabry disease is mediated by a heat shock protein-transient receptor potential cation channel A1 axis
Two-thirds of patients with Fabry disease suffer debilitating pain attacks triggered by exercise, fever, and exposure to environmental heat. These patients face an even greater risk of heat-related episodic pain in the face of global climate change. Almost nothing is known about the biological mechanisms underlying heat-induced pain crises in Fabry disease, and there is no preclinical model available to study Fabry crises. Here, we established the first model of heat-induced pain attacks in Fabry disease by exposing transgenic Fabry rats to environmental heat. Heat exposure precipitated robust mechanical hypersensitivity, closely matching temporal features reported by patients with Fabry disease. At the cellular level, heat exposure sensitized Fabry dorsal root ganglia neurons to agonists for transient receptor potential cation channel A1 (TRPA1), but not transient potential cation channel vanilloid 1. The heat shock response, which normally confers heat-resilience, was impaired in Fabry disease, and we demonstrated that heat shock proteins (HSP70 and HSP90) regulate TRPA1. Strikingly, pharmacologically inhibiting HSP90 completely prevented cellular and behavioral sensitization by environmental heat in Fabry disease. Together, this work establishes the first model of episodic pain in Fabry disease, implicates the heat shock response in heat-evoked pain episodes, and identifies a novel heat shock protein-TRPA1 regulatory axis.
- 3 October 2025
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (2) , 443-454
Episodic pain in Fabry disease is mediated by a heat shock protein-transient receptor potential cation channel A1 axis
Two-thirds of patients with Fabry disease suffer debilitating pain attacks triggered by exercise, fever, and exposure to environmental heat. These patients face an even greater risk of heat-related episodic pain in the face of global climate change. Almost nothing is known about the biological mechanisms underlying heat-induced pain crises in Fabry disease, and there is no preclinical model available to study Fabry crises. Here, we established the first model of heat-induced pain attacks in Fabry disease by exposing transgenic Fabry rats to environmental heat. Heat exposure precipitated robust mechanical hypersensitivity, closely matching temporal features reported by patients with Fabry disease. At the cellular level, heat exposure sensitized Fabry dorsal root ganglia neurons to agonists for transient receptor potential cation channel A1 (TRPA1), but not transient potential cation channel vanilloid 1. The heat shock response, which normally confers heat-resilience, was impaired in Fabry disease, and we demonstrated that heat shock proteins (HSP70 and HSP90) regulate TRPA1. Strikingly, pharmacologically inhibiting HSP90 completely prevented cellular and behavioral sensitization by environmental heat in Fabry disease. Together, this work establishes the first model of episodic pain in Fabry disease, implicates the heat shock response in heat-evoked pain episodes, and identifies a novel heat shock protein-TRPA1 regulatory axis.
- Open Access
Episodic pain in Fabry disease is mediated by a heat shock protein-TRPA1 axis
Two-thirds of patients with Fabry disease suffer debilitating pain attacks triggered by exercise, fever, and exposure to environmental heat. These patients face an even greater risk of heat-related episodic pain in the face of global climate change. Almost nothing is known about the biological mechanisms underlying heat-induced pain crises in Fabry disease, and there is no preclinical model available to study Fabry crises. Here, we established the first model of heat-induced pain attacks in Fabry disease by exposing transgenic Fabry rats to environmental heat. Heat exposure precipitated robust mechanical hypersensitivity, closely matching temporal features reported by patients with Fabry disease. At the cellular level, heat exposure sensitized Fabry dorsal root ganglia (DRG) neurons to agonists for transient receptor potential cation channel A1 (TRPA1), but not TRPV1. The heat shock response, which normally confers heat-resilience, was impaired in Fabry disease, and we demonstrated that heat shock proteins (HSP70 and HSP90) regulate TRPA1. Strikingly, pharmacologically inhibiting HSP90 completely prevented cellular and behavioral sensitization by environmental heat in Fabry disease. Together, this work establishes the first model of episodic pain in Fabry disease, implicates the heat shock response in heat-evoked pain episodes, and identifies a novel heat shock protein-TRPA1 regulatory axis. Abstract Figure:
Open AccessEpisodic pain in Fabry disease is mediated by a heat shock protein-TRPA1 axis
Two-thirds of patients with Fabry disease suffer debilitating pain attacks triggered by exercise, fever, and exposure to environmental heat. These patients face an even greater risk of heat-related episodic pain in the face of global climate change. Almost nothing is known about the biological mechanisms underlying heat-induced pain crises in Fabry disease, and there is no preclinical model available to study Fabry crises. Here, we established the first model of heat-induced pain attacks in Fabry disease by exposing transgenic Fabry rats to environmental heat. Heat exposure precipitated robust mechanical hypersensitivity, closely matching temporal features reported by patients with Fabry disease. At the cellular level, heat exposure sensitized Fabry dorsal root ganglia (DRG) neurons to agonists for transient receptor potential cation channel A1 (TRPA1), but not TRPV1. The heat shock response, which normally confers heat-resilience, was impaired in Fabry disease, and we demonstrated that heat shock proteins (HSP70 and HSP90) regulate TRPA1. Strikingly, pharmacologically inhibiting HSP90 completely prevented cellular and behavioral sensitization by environmental heat in Fabry disease. Together, this work establishes the first model of episodic pain in Fabry disease, implicates the heat shock response in heat-evoked pain episodes, and identifies a novel heat shock protein-TRPA1 regulatory axis. Abstract Figure:
- Open Access
- 7 March 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (8)
Fabry disease Schwann cells release p11 to induce sensory neuron hyperactivity
Patients with Fabry disease suffer from chronic debilitating pain and peripheral sensory neuropathy with minimal treatment options, but the cellular drivers of this pain are unknown. Here, we propose a mechanism we believe to be novel in which altered signaling between Schwann cells and sensory neurons underlies the peripheral sensory nerve dysfunction we observed in a genetic rat model of Fabry disease. Using in vivo and in vitro electrophysiological recordings, we demonstrated that Fabry rat sensory neurons exhibited pronounced hyperexcitability. Schwann cells probably contributed to this finding because application of mediators released from cultured Fabry Schwann cells induced spontaneous activity and hyperexcitability in naive sensory neurons. We examined putative algogenic mediators using proteomic analysis and found that Fabry Schwann cells released elevated levels of the protein p11 (S100A10), which induced sensory neuron hyperexcitability. Removal of p11 from Fabry Schwann cell media caused hyperpolarization of neuronal resting membrane potentials, indicating that p11 may contribute to the excessive neuronal excitability caused by Fabry Schwann cells. These findings demonstrate that sensory neurons from rats with Fabry disease exhibit hyperactivity caused in part by Schwann cell release of the protein p11.
- 7 March 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (8)
Open AccessFabry disease Schwann cells release p11 to induce sensory neuron hyperactivity
Patients with Fabry disease suffer from chronic debilitating pain and peripheral sensory neuropathy with minimal treatment options, but the cellular drivers of this pain are unknown. Here, we propose a mechanism we believe to be novel in which altered signaling between Schwann cells and sensory neurons underlies the peripheral sensory nerve dysfunction we observed in a genetic rat model of Fabry disease. Using in vivo and in vitro electrophysiological recordings, we demonstrated that Fabry rat sensory neurons exhibited pronounced hyperexcitability. Schwann cells probably contributed to this finding because application of mediators released from cultured Fabry Schwann cells induced spontaneous activity and hyperexcitability in naive sensory neurons. We examined putative algogenic mediators using proteomic analysis and found that Fabry Schwann cells released elevated levels of the protein p11 (S100A10), which induced sensory neuron hyperexcitability. Removal of p11 from Fabry Schwann cell media caused hyperpolarization of neuronal resting membrane potentials, indicating that p11 may contribute to the excessive neuronal excitability caused by Fabry Schwann cells. These findings demonstrate that sensory neurons from rats with Fabry disease exhibit hyperactivity caused in part by Schwann cell release of the protein p11.
- 2 February 2024
- Published by Wolters Kluwer Health in Pain
- Vol. 165 (7) , 1569-1582
High-speed imaging of evoked rodent mechanical behaviors yields variable results that are not predictive of inflammatory injury
Few analgesics identified using preclinical models have successfully translated to clinical use. These translational limitations may be due to the unidimensional nature of behavioral response measures used to assess rodent nociception. Advances in high-speed videography for pain behavior allow for objective quantification of nuanced aspects of evoked paw withdrawal responses. However, whether videography-based assessments of mechanical hypersensitivity outperform traditional measurement reproducibility is unknown. First, we determined whether high-speed videography of paw withdrawal was reproducible across experimenters. Second, we examined whether this method distinguishes behavioral responses exhibited by naive mice and mice with complete Freund's adjuvant (CFA)-induced inflammation. Twelve experimenters stimulated naive C57BL/6 mice with varying mechanical stimuli. Paw withdrawal responses were recorded with high-speed videography and scored offline by one individual. Our group was unable to replicate the original findings produced by high-speed videography analysis. Surprisingly, ∼80% of variation was not accounted for by variables previously reported to distinguish between responses to innocuous and noxious stimuli (paw height, paw velocity, and pain score), or by additional variables (experimenter, time-of-day, and animal), but rather by unidentified factors. Similar high-speed videography assessments were performed in CFA- and vehicle-treated animals, and the cumulative data failed to reveal an effect of CFA injection on withdrawal as measured by high-speed videography. This study does not support using paw height, velocity, or pain score measurements from high-speed recordings to delineate behavioral responses to innocuous and noxious stimuli. Our group encourages the continued use of traditional mechanical withdrawal assessments until additional high-speed withdrawal measures are validated in established pain models.
- 2 February 2024
- Published by Wolters Kluwer Health in Pain
- Vol. 165 (7) , 1569-1582
High-speed imaging of evoked rodent mechanical behaviors yields variable results that are not predictive of inflammatory injury
Few analgesics identified using preclinical models have successfully translated to clinical use. These translational limitations may be due to the unidimensional nature of behavioral response measures used to assess rodent nociception. Advances in high-speed videography for pain behavior allow for objective quantification of nuanced aspects of evoked paw withdrawal responses. However, whether videography-based assessments of mechanical hypersensitivity outperform traditional measurement reproducibility is unknown. First, we determined whether high-speed videography of paw withdrawal was reproducible across experimenters. Second, we examined whether this method distinguishes behavioral responses exhibited by naive mice and mice with complete Freund's adjuvant (CFA)-induced inflammation. Twelve experimenters stimulated naive C57BL/6 mice with varying mechanical stimuli. Paw withdrawal responses were recorded with high-speed videography and scored offline by one individual. Our group was unable to replicate the original findings produced by high-speed videography analysis. Surprisingly, ∼80% of variation was not accounted for by variables previously reported to distinguish between responses to innocuous and noxious stimuli (paw height, paw velocity, and pain score), or by additional variables (experimenter, time-of-day, and animal), but rather by unidentified factors. Similar high-speed videography assessments were performed in CFA- and vehicle-treated animals, and the cumulative data failed to reveal an effect of CFA injection on withdrawal as measured by high-speed videography. This study does not support using paw height, velocity, or pain score measurements from high-speed recordings to delineate behavioral responses to innocuous and noxious stimuli. Our group encourages the continued use of traditional mechanical withdrawal assessments until additional high-speed withdrawal measures are validated in established pain models.
- Open Access
- 3 July 2023
- Published by Elsevier in Neurobiology of Pain
- Vol. 14, 100138
ATP-gated potassium channels contribute to ketogenic diet-mediated analgesia in mice
- 3 July 2023
- Published by Elsevier in Neurobiology of Pain
- Vol. 14, 100138
Open AccessATP-gated potassium channels contribute to ketogenic diet-mediated analgesia in mice
- Open Access
ATP-Gated Potassium Channels Contribute to Ketogenic Diet-Mediated Analgesia in Mice
Chronic pain is a substantial health burden and options for treating chronic pain remain minimally effective. Ketogenic diets are emerging as well-tolerated, effective therapeutic strategies in preclinical models of chronic pain, especially diabetic neuropathy. We tested whether a ketogenic diet is antinociceptive through ketone oxidation and related activation of ATP-gated potassium (K ATP ) channels in mice. We demonstrate that consumption of a ketogenic diet for one week reduced evoked nocifensive behaviors (licking, biting, lifting) following intraplantar injection of different noxious stimuli (methylglyoxal, cinnamaldehyde, capsaicin, or Yoda1) in mice. A ketogenic diet also decreased the expression of p-ERK, an indicator of neuronal activation in the spinal cord, following peripheral administration of these stimuli. Using a genetic mouse model with deficient ketone oxidation in peripheral sensory neurons, we demonstrate that protection against methylglyoxal-induced nociception by a ketogenic diet partially depends on ketone oxidation by peripheral neurons. Injection of tolbutamide, a K ATP channel antagonist, prevented ketogenic diet-mediated antinociception following intraplantar capsaicin injection. Tolbutamide also restored the expression of spinal activation markers in ketogenic diet-fed, capsaicin-injected mice. Moreover, activation of K ATP channels with the K ATP channel agonist diazoxide reduced pain-like behaviors in capsaicin-injected, chow-fed mice, similar to the effects observed with a ketogenic diet. Diazoxide also reduced the number of p-ERK + cells in capsaicin-injected mice. These data support a mechanism that includes neuronal ketone oxidation and activation of K ATP channels to provide ketogenic diet-related analgesia. This study also identifies K ATP channels as a new target to mimic the antinociceptive effects of a ketogenic diet.
Open AccessATP-Gated Potassium Channels Contribute to Ketogenic Diet-Mediated Analgesia in Mice
Chronic pain is a substantial health burden and options for treating chronic pain remain minimally effective. Ketogenic diets are emerging as well-tolerated, effective therapeutic strategies in preclinical models of chronic pain, especially diabetic neuropathy. We tested whether a ketogenic diet is antinociceptive through ketone oxidation and related activation of ATP-gated potassium (K ATP ) channels in mice. We demonstrate that consumption of a ketogenic diet for one week reduced evoked nocifensive behaviors (licking, biting, lifting) following intraplantar injection of different noxious stimuli (methylglyoxal, cinnamaldehyde, capsaicin, or Yoda1) in mice. A ketogenic diet also decreased the expression of p-ERK, an indicator of neuronal activation in the spinal cord, following peripheral administration of these stimuli. Using a genetic mouse model with deficient ketone oxidation in peripheral sensory neurons, we demonstrate that protection against methylglyoxal-induced nociception by a ketogenic diet partially depends on ketone oxidation by peripheral neurons. Injection of tolbutamide, a K ATP channel antagonist, prevented ketogenic diet-mediated antinociception following intraplantar capsaicin injection. Tolbutamide also restored the expression of spinal activation markers in ketogenic diet-fed, capsaicin-injected mice. Moreover, activation of K ATP channels with the K ATP channel agonist diazoxide reduced pain-like behaviors in capsaicin-injected, chow-fed mice, similar to the effects observed with a ketogenic diet. Diazoxide also reduced the number of p-ERK + cells in capsaicin-injected mice. These data support a mechanism that includes neuronal ketone oxidation and activation of K ATP channels to provide ketogenic diet-related analgesia. This study also identifies K ATP channels as a new target to mimic the antinociceptive effects of a ketogenic diet.
- 4 April 2023
- Published by Elsevier in The Journal of Pain
- Vol. 24 (4) , 30-31
ATP-Gated Potassium Channels Contribute To Ketogenic Diet-Mediated Analgesia
- 4 April 2023
- Published by Elsevier in The Journal of Pain
- Vol. 24 (4) , 30-31
ATP-Gated Potassium Channels Contribute To Ketogenic Diet-Mediated Analgesia
- Open Access
Abnormal Intraepidermal Nerve Fiber Density in Disease: A Scoping Review
Background Intraepidermal nerve fiber density (IENFD) has become an important biomarker for neuropathy diagnosis and research. The consequences of reduced IENFD can include sensory dysfunction, pain, and a significant decrease in quality of life. We examined the extent to which IENFD is being used as a tool in human and mouse models and compared the degree of fiber loss between diseases to gain a broader understanding of the existing data collected using this common technique. Methods We conducted a scoping review of publications that used IENFD as a biomarker in human and non-human research. PubMed was used to identify 1,004 initial articles that were then screened to select articles that met the criteria for inclusion. Criteria were chosen to standardize publications so they could be compared rigorously and included having a control group, measuring IENFD in a distal limb, and using protein gene product 9.5 (PGP9.5). Results We analyzed 397 articles and collected information related to publication year, the condition studied, and the percent IENFD loss. The analysis revealed that the use of IENFD as a tool has been increasing in both human and non-human research. We found that IENFD loss is prevalent in many diseases, and metabolic or diabetes-related diseases were the most studied conditions in humans and rodents. Our analysis identified 74 human diseases in which IENFD was affected, with 71 reporting IENFD loss and an overall average IENFD change of -47%. We identified 28 mouse and 21 rat conditions, with average IENFD changes of -31.6 % and - 34.7% respectively. Additionally, we present data describing sub-analyses of IENFD loss according to disease characteristics in diabetes and chemotherapy treatments in humans and rodents. Interpretation Reduced IENFD occurs in a surprising number of human disease conditions. Abnormal IENFD contributes to important complications, including poor cutaneous vascularization, sensory dysfunction, and pain. Our analysis informs future rodent studies so they may better mirror human diseases impacted by reduced IENFD, highlights the breadth of diseases impacted by IENFD loss, and urges exploration of common mechanisms that lead to substantial IENFD loss as a complication in disease.
Open AccessAbnormal Intraepidermal Nerve Fiber Density in Disease: A Scoping Review
Background Intraepidermal nerve fiber density (IENFD) has become an important biomarker for neuropathy diagnosis and research. The consequences of reduced IENFD can include sensory dysfunction, pain, and a significant decrease in quality of life. We examined the extent to which IENFD is being used as a tool in human and mouse models and compared the degree of fiber loss between diseases to gain a broader understanding of the existing data collected using this common technique. Methods We conducted a scoping review of publications that used IENFD as a biomarker in human and non-human research. PubMed was used to identify 1,004 initial articles that were then screened to select articles that met the criteria for inclusion. Criteria were chosen to standardize publications so they could be compared rigorously and included having a control group, measuring IENFD in a distal limb, and using protein gene product 9.5 (PGP9.5). Results We analyzed 397 articles and collected information related to publication year, the condition studied, and the percent IENFD loss. The analysis revealed that the use of IENFD as a tool has been increasing in both human and non-human research. We found that IENFD loss is prevalent in many diseases, and metabolic or diabetes-related diseases were the most studied conditions in humans and rodents. Our analysis identified 74 human diseases in which IENFD was affected, with 71 reporting IENFD loss and an overall average IENFD change of -47%. We identified 28 mouse and 21 rat conditions, with average IENFD changes of -31.6 % and - 34.7% respectively. Additionally, we present data describing sub-analyses of IENFD loss according to disease characteristics in diabetes and chemotherapy treatments in humans and rodents. Interpretation Reduced IENFD occurs in a surprising number of human disease conditions. Abnormal IENFD contributes to important complications, including poor cutaneous vascularization, sensory dysfunction, and pain. Our analysis informs future rodent studies so they may better mirror human diseases impacted by reduced IENFD, highlights the breadth of diseases impacted by IENFD loss, and urges exploration of common mechanisms that lead to substantial IENFD loss as a complication in disease.